UBS reaffirmed its Neutral rating on Novo Nordisk A/S (NVO) with a price target of DKK 295. The European Medicines Agency recommended EU approval of a higher 7.2 mg dose of Wegovy, which showed greater weight loss results. This dosage is also under review in the U.S. and U.K. Novo Nordisk is a leading pharmaceutical company in diabetes and obesity care. While NVO has potential, some AI stocks may offer higher returns. For more information on promising AI stocks, check out our report.

Read more at Yahoo Finance: UBS Reiterates Neutral on Novo Nordisk A/S (NVO) Despite Wegovy Dose Progress